Skip to main content

Table 3 Comparison of antitumour efficacy of single and combined mAbs in the intravenous tumour model

From: Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia

Injected mAbs

Median survival in days

N° of tumour free animal at day 300 (%)

Anti-HLA-DR

45*

0/10

(0%)

Anti-CD5

25*

0/10

(0%)

Anti-CD71

29*

0/6

(0%)

Anti-HLA-DR + anti-CD5

> 300**

12/12

(100%)

Anti-CD71 + anti-CD5

45**

2/12

(17%)

Anti-CD71 + anti-HLA-DR

52**

6/12

(50%)

Untreated animals

18.5

0/36

(0%)

  1. *significantly different from irrelevant IgG injected control mice (p < 0.005)
  2. **significantly different from both single antibody treatments (p < 0.05)
Back to article page

Molecular Cancer

ISSN: 1476-4598